Sofinnova Venture Partners X, L.P. 3
3 · Bolt Biotherapeutics, Inc. · Filed Feb 4, 2021
Insider Transaction Report
Form 3
Sofinnova Venture Partners X, L.P.
10% Owner
Holdings
Series C-1 Preferred Stock
Exercise: $0.00→ Common Stock (1,104,209 underlying)Series C-2 Preferred Stock
Exercise: $0.00→ Common Stock (1,200,228 underlying)
Footnotes (3)
- [F1]The Series C-1 Preferred Stock has no expiration date and is convertible into shares of Common Stock of the Issuer at the option of the holder. The shares of Series C-1 Preferred Stock will automatically convert into shares of Common Stock of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer (the "IPO").
- [F2]The shares are held directly by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.
- [F3]The Series C-2 Preferred Stock has no expiration date and is convertible into shares of Common Stock of the Issuer at the option of the holder. The shares of Series C-2 Preferred Stock will automatically convert into shares of Common Stock of the Issuer on a 1-to-1 basis upon closing of the IPO.